Status:
COMPLETED
Probiotic LR08 Improves Gut and Metabolism
Lead Sponsor:
Wecare Probiotics Co., Ltd.
Conditions:
Healthy Adults
Eligibility:
All Genders
18-45 years
Phase:
NA
Brief Summary
Evaluate the efficacy and safety of LR08 as a dietary supplement compared to a placebo in enhancing intestinal health and immune function in healthy adults.
Eligibility Criteria
Inclusion
- Willing to attend 3 follow-up visits during the intervention period
- Agree to provide blood, urine, and stool samples twice during the intervention period
- Good eyesight, able to read and write, and capable of wearing glasses if needed
- Good hearing and able to fully comprehend all instructions during the intervention
Exclusion
- Presence of digestive diseases, particularly gastrointestinal disorders (e.g., celiac disease, ulcerative colitis, Crohn's disease)
- History of serious neurological conditions (e.g., epilepsy, stroke, severe head trauma, meningitis within the last 10 years, brain surgery, brain tumor, or prolonged coma-not including general anesthesia)
- History of or currently receiving treatment for mental health disorders such as alcohol/drug/substance abuse, schizophrenia, psychosis, or bipolar disorder
- Currently taking medication for depression or low mood
- Presence of internal organ failure (e.g., heart, liver, or kidney failure)
- History of radiation therapy or chemotherapy treatments
- Underwent general anesthesia within the past three years or are scheduled for general anesthesia within the next 3 months during the trial period
- History of hepatitis (B or C), HIV, or syphilis
Key Trial Info
Start Date :
March 10 2025
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 30 2025
Estimated Enrollment :
48 Patients enrolled
Trial Details
Trial ID
NCT06875362
Start Date
March 10 2025
End Date
June 30 2025
Last Update
August 1 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Xu fei
Zhengzhou, Henan, China, 210095